Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: January 18, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Bococizumab

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Bococizumab?

Bococizumab is an investigational drug.

There have been 10 clinical trials for Bococizumab. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2013.

The most common disease conditions in clinical trials are Hyperlipidemias, Dyslipidemias, and Cardiovascular Diseases. The leading clinical trial sponsors are Pfizer, University of California, San Francisco, and San Francisco General Hospital.

There are four US patents protecting this investigational drug and thirty-four international patents.

Recent Clinical Trials for Bococizumab
Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia SubjectsPfizerPhase 3
Bococizumab HIV Evaluation (B-HIVE) StudyPfizerPhase 3
Bococizumab HIV Evaluation (B-HIVE) StudySan Francisco General HospitalPhase 3

See all Bococizumab clinical trials

Clinical Trial Summary for Bococizumab

Top disease conditions for Bococizumab
Top clinical trial sponsors for Bococizumab

See all Bococizumab clinical trials

US Patents for Bococizumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Bococizumab   Start Trial Peptide-mediated delivery of immunoglobulins across the blood-brain barrier Mayo Foundation for Medical Education and Research (Rochester, MN)   Start Trial
Bococizumab   Start Trial Antigen-binding proteins that activate the leptin receptor REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY)   Start Trial
Bococizumab   Start Trial Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY)   Start Trial
Bococizumab   Start Trial Treatment with anti-PCSK9 antibodies Pfizer Inc. (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Bococizumab

Drugname Country Document Number Estimated Expiration Related US Patent
Bococizumab Argentina 106319 2035-10-12   Start Trial
Bococizumab Australia 2016338851 2035-10-12   Start Trial
Bococizumab Brazil 112018007318 2035-10-12   Start Trial
Bococizumab Canada 3000215 2035-10-12   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.